Evidence map›Paper›PMID 40102270›Full record

Trial reportEuropean archives of psychiatry and clinical neuroscience2025

Cannabidiol attenuates precuneus activation during appetitive cue exposure in individuals with alcohol use disorder.

Tristan Hurzeler, Warren Logge, Joshua Watt, I S McGregor, Anastasia Suraev, Paul S Haber, Kirsten C Morley

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European archives of psychiatry and clinical neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. The neural and psychophysiological effects of cannabidiol in youth with alcohol use disorder: A randomized controlled clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2025
    Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tristan HurzelerSpecialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Warren LoggeSpecialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Joshua WattSpecialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
I S McGregorLambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, NSW, Australia.
Anastasia SuraevLambert Initiative for Cannabinoid Therapeutics, University of Sydney, Sydney, NSW, Australia.
Paul S HaberSpecialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Kirsten C MorleySpecialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia. kirsten.morley@sydney.edu.au.ORCID http://orcid.org/0000-0002-0868-9928

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alcohol use disorder (AUD) is a prevalent psychiatric condition characterised by problematic alcohol consumption and craving, necessitating the exploration of novel therapeutic interventions. Cannabidiol (CBD), a non-psychoactive component of cannabis, has shown potential in modulating neural processes associated with substance use disorders including AUD. This study aimed to investigate the effect of CBD on alcohol cue-induced activation of neurocircuitry associated with alcohol craving, and impact on mood, craving, and cognitive functioning in individuals with AUD. In a cross-over, double-blind, randomized trial, 22 non-treatment seeking individuals (M = 29 years) diagnosed with AUD (DSM-V) received either 800 mg of CBD or a matched placebo, completing two respective fMRI sessions. The primary outcome was neural activation in response to alcohol versus control visual cues, measured using a functional magnetic resonance imaging (fMRI) alcohol cue reactivity task. Secondary outcomes included assessments of mood, craving, and cognitive functioning. Region of interest analyses showed no differences in alcohol cue-elicited activation between the CBD and placebo conditions. However, exploratory whole-brain analysis indicated a significant treatment effect of CBD in the precuneus which was independent of cue specificity. There were no significant treatment effects of CBD compared to placebo on acute craving, mood, or cognitive functioning. In non treatment seeking individuals with AUD, CBD modulates precuneus activity during alcohol cue exposure. Further studies examining the effect of CBD on treatment-seeking AUD individuals are warranted.

Indexed as

AlcoholismCannabidiolCravingCuesParietal LobeAdultAffectCross-Over StudiesDouble-Blind MethodFemaleHumansMagnetic Resonance ImagingMaleYoung AdultCannabidiolAlcohol use disorderCannabidiolCue reactivityNeuroimagingPharmacotherapy

Identifiers

PMID40102270
PMCPMC12589260

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.